{"disease":{"id":"recurrent-squamous-cell-lung-carcinoma","name":"recurrent squamous cell lung carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02154490","title":"Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1864,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT00946712","title":"S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1333,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT02785952","title":"Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":275,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT03373760","title":"Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT03845296","title":"Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT02955290","title":"CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":51,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT03377556","title":"Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT04007744","title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02417701","title":"Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01737502","title":"Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT03574753","title":"Lung-MAP S1400K: c-MET Positive","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT03299088","title":"Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Jonathan Riess","has_results":true},{"nct_id":"NCT03229278","title":"Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT03758781","title":"IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false},{"nct_id":"NCT02926638","title":"Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}